Background: Due to limited enrollment in landmark trials of patients with a BMI> 30 or
weight> 100 kg for apixaban and rivaroxaban, the International Society of Thrombosis and …

In the United States, over the past two decades, the prevalence of severe obesity (body
mass index [BMI]> 40 kg/m 2) in adults has almost doubled (from 4.7% to 9.2%). 1 Obesity is …

In recent years there has been a significant increase in the prevalence of both obesity and
atrial fibrillation (AF), with up to about 40% of the US population now being considered …

Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …

BACKGROUND: Direct-acting oral anticoagulants (DOACs) represent an alternative to
vitamin K antagonists in the treatment of venous thromboembolism (VTE); however …

Patients at extremes of body weight are underrepresented in randomized controlled trials of
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …

Abstract Purpose Factor Xa Inhibitors have emerged as a first-line agent in the management
of non-valvular atrial fibrillation (NVAF), but there is a need for additional data surrounding …

Background Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and
venous thromboembolism (VTE) and both occur more frequently in obese patients …

Direct oral anticoagulants (DOACs) are a favored treatment to prevent stroke in patients with
atrial fibrillation (AF). There are limited data concerning the efficacy and safety of DOACs in …

DISCUSSION: Morbidly obese (BMI more than equal to 40 and weight> 120 kg) patients are
at high risk of failure with Factor Xa inhibitors like apixaban and rivaroxaban. The current …